

BOVIE MEDICAL Corp  
Form 10-Q  
August 02, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

**x      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the Quarterly Period Ended June 30, 2016**

**OR**

**..      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the Period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission file number 0-12183**

**BOVIE MEDICAL CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation  
or organization)

**11-2644611**  
(IRS Employer Identification No.)

**4 Manhattanville Road, Suite 106, Purchase, NY 10577**

Edgar Filing: BOVIE MEDICAL Corp - Form 10-Q

(Address of principal executive offices)

**(914) 468-4009**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant's common stock \$.001 par value outstanding as of July 22, 2016 was 27,194,251.

**BOVIE MEDICAL CORPORATION**

**INDEX TO FORM 10-Q**

**FOR THE QUARTER ENDED JUNE 30, 2016**

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	<b>3</b>
<b><u>Item 1. Financial Statements</u></b>	
<u>Consolidated Balance Sheets – June 30, 2016 and December 31, 2015</u>	3
<u>Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2016 and 2015</u>	5
<u>Consolidated Statements of Stockholders' Equity for the Six Months Ended June 30, 2016</u>	6
<u>Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and 2015</u>	7
<u>Notes to Consolidated Financial Statements</u>	8
<b><u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	<b>15</b>
<b><u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u></b>	<b>23</b>
<b><u>Item 4. Controls and Procedures</u></b>	<b>23</b>
<b><u>PART II. OTHER INFORMATION</u></b>	<b>24</b>
<b><u>Item 1. Legal Proceedings</u></b>	<b>24</b>
<b><u>Item 1A. Risk Factors</u></b>	<b>24</b>
<b><u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	<b>24</b>
<b><u>Item 3. Defaults Upon Senior Securities</u></b>	<b>24</b>
<b><u>Item 4. Mine Safety Disclosures</u></b>	<b>24</b>
<b><u>Item 5. Other Information</u></b>	<b>24</b>
<b><u>Item 6. Exhibits</u></b>	<b>24</b>
<u>Signatures</u>	25

**PART I. FINANCIAL INFORMATION****ITEM 1: FINANCIAL STATEMENTS****BOVIE MEDICAL CORPORATION****CONSOLIDATED BALANCE SHEETS****JUNE 30, 2016 AND DECEMBER 31, 2015**

(in thousands)

	<b>June 30, 2016 (Unaudited)</b>	<b>December 31, 2015</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 9,324	\$ 11,805
Restricted cash	779	839
Trade accounts receivable, net	3,506	2,925
Inventories, net	6,415	5,957
Prepaid expenses and other current assets	536	516
<b>Total current assets</b>	<b>20,560</b>	<b>22,042</b>
Property and equipment, net	6,536	6,810
Brand name and trademark	1,510	1,510
Purchased technology and license rights, net	269	323
Goodwill	185	185
Deposits	123	123
Deferred tax asset	21	25
Other assets	386	430
<b>Total assets</b>	<b>\$ 29,590</b>	<b>\$ 31,448</b>

The accompanying notes are an integral part of the consolidated financial statements.



Table of Contents

**BOVIE MEDICAL CORPORATION**  
**CONSOLIDATED BALANCE SHEETS**  
**JUNE 30, 2016 AND DECEMBER 31, 2015**  
**(CONTINUED)** (in thousands)

	<b>June 30, 2016 (Unaudited)</b>	<b>December 31, 2015</b>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 1,774	\$ 1,214
Accrued payroll	378	321
Accrued vacation	380	228
Current portion of mortgage note payable	239	239
Accrued and other liabilities	1,844	2,119
Total current liabilities	4,615	4,121
Mortgage note payable, net of current portion	2,814	2,934
Notes payable	140	140
Deferred rents	17	18
Deferred tax liability	564	564
Derivative liabilities	139	267
Total liabilities	8,289	8,044
Commitments and Contingencies (see Notes 9 and 10)		
Stockholders' equity:		
Series B convertible preferred stock, par value \$.001; 3,588,139 issued and 1,975,639 outstanding as of June 30, 2016 and December 31, 2015, respectively	2	2
Common stock, par value \$.001 par value; 40,000,000 shares authorized; 27,194,251 issued and 27,051,172 outstanding as of June 30, 2016 and December 31, 2015, respectively	27	27
Additional paid-in capital	43,219	42,859
Accumulated deficit	(21,947)	(19,484)
Total stockholders' equity	21,301	23,404
Total liabilities and stockholders' equity	\$ 29,590	\$ 31,448

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

**BOVIE MEDICAL CORPORATION**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2016 AND 2015**

**(UNAUDITED) (in thousands except per share data)**

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
Sales	\$ 9,295	\$ 7,274	\$ 17,070	\$ 13,402
Cost of sales	4,595	4,134	9,048	7,588
Gross profit	4,700	3,140	8,022	5,814
Other costs and expenses:				
Research and development	592	505	1,259	951
Professional services	396	313	753	644
Salaries and related costs	2,200	1,868	4,300	3,821
Selling, general and administrative	2,022	2,002	4,213	4,219
Total other costs and expenses	5,210	4,688	10,525	9,635
Loss from operations	(510)	(1,548)	(2,503)	(3,821)
Interest expense, net	(50)	(39)	(88)	(80)
Change in fair value of liabilities, net	41	90	128	1,534
Total other income (expense), net	(9)	51	40	1,454
Loss before income taxes	(519)	(1,497)	(2,463)	(2,367)
Income tax benefit, net	--	--	--	(8)
Net loss	\$ (519)	\$ (1,497)	\$ (2,463)	\$ (2,375)
Accretion on convertible preferred stock	--	--	--	(222)
Gain on conversion of warrants and preferred shares, net	--	--	--	13,956
Net income (loss) attributable to common shareholders	\$ (519)	\$ (1,497)	\$ (2,463)	\$ 11,359
Income (loss) per share				
Basic	(0.02)	(0.06)	(0.09)	0.53
Diluted	(0.02)	(0.06)	(0.09)	0.41



Edgar Filing: BOVIE MEDICAL Corp - Form 10-Q

Weighted average number of shares outstanding- basic	27,051	24,435	27,051	21,555
Weighted average number of shares outstanding - dilutive	27,051	24,435	27,051	24,251

The accompanying notes are an integral part of the consolidated financial statements.

[Table of Contents](#)

**BOVIE MEDICAL CORPORATION**  
**CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY**  
**FOR THE SIX MONTHS ENDED JUNE 30, 2016**  
**(unaudited) (in thousands)**

	<b>Preferred Stock</b>		<b>Common Stock</b>		<b>Additional</b>		<b>Deficit</b>		<b>Total</b>	
	<b>Shares</b>	<b>Par Value</b>	<b>Shares</b>	<b>Par Value</b>	<b>Paid-in</b>	<b>Capital</b>				
December 31, 2015	1,976	\$ 2	27,051	\$ 27	\$ 42,859	\$ (19,484)	\$		\$	23,404
Stock based compensation	-	-	-	-	360	-				360
Net loss	-	-	-	-	-	(2,463)				(2,463)
June 30, 2016	1,976	\$ 2	27,051	\$ 27	\$ 43,219	\$ (21,947)	\$		\$	21,301

The accompanying notes are an integral part of the consolidated financial statements

Table of Contents

**BOVIE MEDICAL CORPORATION**

**CONSOLIDATED STATEMENT OF CASH FLOWS**

**FOR THE SIX MONTHS ENDED JUNE 30, 2016 AND 2015**

**(unaudited) (in thousands)**

	2016	2015
<b>Cash flows from operating activities</b>		
Net loss	\$ (2,463)	\$ (2,375)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	355	421
Provision for (recovery of) inventory obsolescence	334	(138)
Gain on disposal of property and equipment, net	14	-
Stock based compensation	360	242
Non cash other (income) loss - warrants	(128)	(1,534)
<b>Changes in current assets and liabilities:</b>		
Trade receivables	(581)	(49)
Prepaid expenses	(20)	(159)
Inventories	(792)	(486)
Deposits and other assets	44	(128)
Accounts payable	560	190
Accrued and other liabilities	(63)	(105)
Net cash used in operating activities	(2,380)	(4,121)
<b>Cash flows from investing activities</b>		
Purchases of property and equipment	(41)	(462)
Net cash used in investing activities	(41)	(462)
<b>Cash flows from financing activities</b>		
Proceeds from stock options/warrants exercised	-	1,466
Change in restricted cash	60	60
Change in mortgage note payable	(120)	(120)
Proceeds from issuance of common shares, net	-	11,531
Net cash provided by (used in) financing activities	(60)	12,937
Net change in cash and cash equivalents	(2,481)	8,354
<b>Cash and cash equivalents, beginning of period</b>	11,805	5,733
<b>Cash and cash equivalents, end of period</b>	\$ 9,324	\$ 14,087

Cash paid during the six months ended June 30, 2016 and 2015 for:

**Cash paid for:**

Interest	\$	50	\$	80
Income taxes	\$	-	\$	-

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents

**BOVIE MEDICAL CORPORATION**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(UNAUDITED)**

**NOTE 1. BASIS OF PRESENTATION**

Unless the context otherwise indicates, the terms "we," "our," "us," "Bovie," and similar terms refer to Bovie Medical Corporation and its consolidated subsidiaries.

The accompanying unaudited consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015. These financial statements reflect all adjustments that are necessary for a fair presentation of results of operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.

**NOTE 2. INVENTORIES**

Inventories are stated at the lower of cost or market. Finished goods and work-in-process inventories include material, labor, and overhead costs. Factory overhead costs are allocated to inventory manufactured in-house based upon labor hours.

Inventories at June 30, 2016 and December 31, 2015 were as follows (in thousands):

	<b>June 30, 2016</b>	<b>December 31, 2015</b>
Raw materials	\$ 5,563	\$ 4,627
Work in process	481	483
Finished goods	1,938	2,080

Gross inventories	7,982	7,190
Less: reserve for obsolescence	(1,567)	(1,233)
Net inventories	\$ 6,415	\$ 5,957

### NOTE 3. INTANGIBLE ASSETS

At June 30, 2016 and December 31, 2015, intangible assets consisted of the following (in thousands):

	June 30, 2016	December 31, 2015
Brand name and trademark (life indefinite)	\$ 1,510	\$ 1,510
Purchased technology (9-17 year lives)	1,441	1,441
Less: accumulated amortization	(1,172)	(1,118)
Purchased technology, net	\$ 269	\$ 323

Table of Contents

With respect to our trademark and brand name, we continue to market products, release new products and product extensions and maintain and promote these trademarks and brand name in the marketplace through legal registration and such methods as advertising, medical education and trade shows. It is our belief that these trademarks and brand names will generate cash flow for an indefinite period of time. Therefore, we believe our trademarks and brand name intangible assets are not impaired.

Amortization of intangibles, which is included in depreciation and amortization in the accompanying statements of cash flows, was approximately \$54,000 during each of the respective six month periods ended June 30, 2016 and 2015.

**NOTE 4. NEW ACCOUNTING PRONOUNCEMENTS**

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2014-09, *Revenue from Contracts with Customers*, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No. 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for us on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the effect that ASU No. 2014-09 will have on our consolidated financial statements and related disclosures.

No other new accounting pronouncement issued or effective during the period had or is expected to have a material impact on our consolidated financial statements or disclosures.

**NOTE 5. FAIR VALUE MEASUREMENTS**

Certain assets and liabilities that are measured at fair value on a recurring basis are measured in accordance with FASB ASC Topic 820-10-05, *Fair Value Measurements*. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.

The statement requires fair value measurement be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Our derivative financial instruments that are measured at fair value on a recurring basis are all measured at fair value using Level 3 inputs. Level 3 inputs are unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.



Table of Contents

The following represents a reconciliation of the changes in fair value of warrants measured at fair value using Level 3 inputs during the six months ended June 30, 2016:

(in \$ thousands)	<b>2013 Placement Agent Warrants</b>
Balance, December 31, 2015	\$ 267
Change in fair value	(128)
Balance, June 30, 2016 <sup>(1)</sup>	\$ 139

- (1) The warrants are valued using a trinomial lattice valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions used in the model at June 30, 2016 included the market price of our common stock, an expected dividend yield of zero, the remaining period to the expiration date of the warrants, expected volatility of our common stock over the remaining life of the warrants of 49.5%, estimated based on a review of our historical volatility, and risk-free rates of return of 0.7% for the 2013 warrants based on constant maturity rates published by the U.S. Federal Reserve, applicable to the remaining life of the warrants. We also take into consideration a probability assumption for anti-dilution.

**NOTE 6. EARNINGS PER SHARE (in thousands, except EPS)**

We compute basic earnings per share ("basic EPS") by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share ("diluted EPS") gives effect to all dilutive potential shares outstanding. The following table provides the computation of basic and diluted earnings per share for the three and six month periods ending June 30, 2016 and 2015:

(in thousands, except per share data)	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
Numerator:				
Net income (loss) available to common shareholders	\$ (519)	\$ (1,497)	\$ (2,463)	\$ 11,359
Effect of dilutive securities				
Derivative liability - warrants	\$ (41)	\$ -	\$ (128)	\$ (1,534)

Edgar Filing: BOVIE MEDICAL Corp - Form 10-Q

Accretion on convertible preferred stock	-	-	-	222
Numerator for diluted income (loss) per common share	\$ (560)	\$ (1,497)	\$ (2,591)	\$ 10,047
Denominator:				
Weighted average shares used to compute basic income (loss) per common share	27,051	24,435	27,051	21,555
Effect of dilutive securities:				
Derivative liability - warrants	-	-	-	82
Convertible preferred stock	-	-	-	2,305
Stock options	-	-	-	309
Denominator for diluted income (loss) per common share	27,051	24,435	27,051	24,251
Basic income (loss) per common share	\$ (0.02)	\$ (0.06)	\$ (0.09)	\$ 0.53
Diluted income (loss) per common share	\$ (0.02)	\$ (0.06)	\$ (0.09)	\$ 0.41

Table of Contents

For the three months ended June 30, 2016, the potential conversion of Series B Preferred Stock into 3,951,278 shares of common stock was excluded from the computation of diluted earnings per share as the effect is anti-dilutive.

For the three months ended June 30, 2016, approximately \$41,000 of the gain on the fair market valuation of the derivative liability was excluded in the computation of diluted earnings per share as the effect is anti-dilutive.

For the six months ended June 30, 2016, the exercise of warrants, preferred stock, and options were excluded from the computation of fully diluted earnings per share because their effect was antidilutive.

For the three months ended June 30, 2015, options and warrants to purchase approximately 277,000 shares of common stock and approximately \$90,000 of the gain on the fair market valuation of the derivative liabilities were excluded in the computation of diluted earnings per share because their effects were anti-dilutive, while the potential conversion of Series B Preferred Stock into 3,951,278 shares of common stock was excluded from the computation of diluted earnings per share as the effect is anti-dilutive.

For the six months ended June 30, 2015, warrants to purchase approximately 82,000 shares of common stock and approximately \$1,534,000 of the gain on the fair market valuation of the derivative liabilities were included in the computation of dilutive earnings per share and options to purchase approximately 309,000 shares of common stock were included in the computation of dilutive earnings per share because their effect was dilutive. The conversion of Series B Preferred Stock into 2,305,000 shares of common stock was included in the computation of diluted earnings per share as the effect is dilutive.

**NOTE 7. STOCK-BASED COMPENSATION**

Under our stock option plans, our board of directors may grant options to purchase common shares to our key employees, officers, non-employees, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, *Compensation – Stock Compensation*, with option expense amortized over the vesting period based on the trinomial lattice option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of our expense. During the six months ended June 30, 2016, we expensed approximately \$360,000 in stock-based compensation.

Activity in our stock options during the period ended June 30, 2016 was as follows:

	<b>Number of</b>	<b>Weighted</b>
	<b>Options</b>	<b>Average</b>
	<b>(in</b>	<b>Exercise</b>
	<b>thousands)</b>	<b>Price</b>
Outstanding at December 31, 2015	3,131	\$ 3.38
Granted	626	\$ 1.74
Outstanding at June 30, 2016	3,757	\$ 3.09

The grant date fair value of options granted during the first six months of 2016 were estimated on the grant date using a trinomial lattice option-pricing model and the following assumptions: expected volatility of 49.5%, expected term of between 5-8 years, risk-free interest rate of 0.71%, and expected dividend yield of 0%.

On June 30, 2016, the Company entered into a sales channel partnership agreement with Arteriocyte LLC. As part of the agreement, Arteriocyte was granted 240,000 ten-year options with a four year performance based vesting schedule and an exercise price of \$1.64 per option.

Expected volatility is based on a five year average of the historical volatility of the Company's stock. The risk-free rate is based on the rate of U.S. Treasury zero-coupon issues with a remaining term equal to the expected life of the options. The Company uses historical data to estimate pre-vesting forfeiture rates.

Table of Contents

**NOTE 8. INCOME TAXES**

The Company's income tax provision was \$0 with an effective tax rate of 0% for the three and six months ended June 30, 2016. The Company's effective tax rate differs from the statutory rate primarily due to the valuation allowance on the Company's net deferred tax assets with finite life.

As a result of historical losses, the Company recorded a valuation allowance on the net deferred tax asset with a finite life and does not anticipate recording an income tax benefit related to these deferred tax assets. The Company reassesses the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent that the financial results of these operations improve and it becomes more likely than not that the deferred tax assets are realizable.

For the three and six months ended June 30, 2016, we do not believe we had any significant uncertain tax positions nor did we have any interest or penalties related to any significant uncertain tax positions.

The Company is subject to U.S. federal income tax, state income tax and Bulgarian income tax. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused NOL's), we are subject to income tax audits in the jurisdictions in which we operate.

**NOTE 9.COMMITMENTS, CONTINGENCIES AND CONCENTRATIONS**

In March 2014, we entered into a lease for offices located in Purchase, New York, where we are obligated to pay \$9,277 per month for the lease expiring June 14, 2019. The lease is for 3,650 square feet of office space.

In October 2015, pursuant to our acquisition of Bovie Bulgaria, we are obligated to pay approximately \$6,350 per month for the lease expiring on December 31, 2016.

The following is a schedule of approximate future minimum lease payments under operating leases having remaining terms in excess of one year as of June 30, 2016 for the calendar years ending December 31, 2016 and thereafter (in thousands):

2016	\$	95
2017		114
2018		117
2019		120
Thereafter		30
Total	\$	476

Rent expense approximated \$82,280 and \$52,925 for the six month periods ending June 30, 2016 and 2015, respectively.

Other future contractual obligations for other agreements with initial terms greater than one year and agreements to purchase materials in the normal course of business are summarized as follows (in thousands):

Description	Year Ending December 31,					Thereafter
	2016	2017	2018	2019		
Purchase commitments	\$ 3,482	\$ -	\$ -	\$ -	\$ -	-
Mortgage debt	239	239	239	2,336		-
Total	\$ 3,721	\$ 239	\$ 239	\$ 2,336	\$ -	-

## Litigation

In the normal course of business, we are subject, from time to time, to legal proceedings, lawsuits and claims. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. If any of these matters arise in the future, it could affect the operating results of any one or more quarters.

We expense costs of litigation related to contingencies in the periods in which the costs are incurred.

Table of Contents

**Concentrations**

Our ten largest customers accounted for approximately 56.2% and 57.1% of revenues for the six months ended June 30, 2016 and 2015, respectively. For the six months ended June 30, 2016, McKesson and NDC accounted for 16.5% and 9.6% of our sales, while for the same six month period ended in 2015, McKesson and NDC accounted for 17.7% and 13.2% of our sales, respectively.

**NOTE 10. RELATED PARTY TRANSACTIONS**

Several relatives of Nikolay Shilev, Bovie Bulgaria's Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev's spouse is an employee of the company working in the Accounting department in Bulgaria. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev's sister is the Manager of Production and Human Resources. Svetoslav Shilev, Mr. Shilev's son is an Engineer in the Quality Assurance department in Bulgaria.

A relative of Moshe Citronowicz, Bovie's Senior Vice President, is considered a related party. Arik Zoran is a consultant of the Company doing business as AR Logic, Inc., a consulting firm owned by Arik Zoran, Mr. Citronowicz's brother. On March 1, 2013 the Company amended the Consulting Services Agreement dated January 2011, extending the term of the existing agreement until December 31, 2014. The agreement shall automatically renew for additional one year periods, unless either party gives written notice of its desire not to renew at least one year prior to the expiration of the initial Term or renewal term. The agreement with AR Logic provides for a monthly retainer for engineering support for our existing generator product line and a separate hourly based fee structure for additional consulting related to new product lines. AR Logic has a royalty contract with us related to the creation and design of proprietary technology that is used in some of our generators. AR Logic was paid consulting fees of approximately \$76,662 and \$178,410 during the six months ended June 30, 2016 and 2015, respectively.

A second relative of Mr. Citronowicz is considered a related party. Yechiel Tsitrinovich is also a brother of Mr. Citronowicz, and acts as a consultant to the Company related to research and development of certain products. Mr. Tsitrinovich has a royalty contract with us related to the creation and design of a proprietary technology that is used in some of our generators. On June 6, 2016, the Company notified Mr. Tsitrinovich of our intent to terminate his contract effective January 31, 2017. Mr. Tsitrinovich was paid a combination of consulting fees and royalties on previous product designs approximating \$36,798 and \$38,817 during the six months ended June 30, 2016 and 2015, respectively.

**NOTE 11. LONG TERM DEBT**

On June 28, 2016, the Company entered into a transaction with Bank of Tampa, a Florida banking corporation ("Lender") wherein Lender amended the terms of a mortgage loan ("the Loan") originally executed on March 20, 2014 with a principal amount of \$3,592,000. The Initial Maturity Date of the Loan was extended to July 20, 2019 from March 19, 2017, and the Extended Maturity Date was amended to July 20, 2024 from March 20, 2022. In addition, the Lender released as collateral to the Loan, the Company's working capital accounts in exchange for a negative

covenant limited to \$2,000,000 of the aggregate indebtedness secured by these accounts.

The obligations under the Loan are secured by a first mortgage and security interest in the Company's Clearwater, Florida facility. In addition, the Company has pledged an interest in a certificate of deposit in the amount of \$779,000 as additional collateral. The amount of the additional collateral required declines on a pro rata basis as principal is paid.

Borrowings under the Loan bear interest at LIBOR plus 3.5%, with a fixed monthly principal payment of \$19,956. The interest rate at June 30, 2016 was 3.965%.

The Loan documents contain customary financial covenants, including a covenant that the Company maintains a minimum liquidity of \$750,000. Should we desire to extend the Loan beyond July 20, 2019, we must maintain a Debt Service Coverage Ratio for each of the preceding four quarters of not less than 1.0 to 1.0.



Table of Contents**NOTE 12. GEOGRAPHIC AND PRODUCT LINE INFORMATION**

International sales represented approximately 16.6% and 15.9% of total revenues for the three and six months ended June 30, 2016, respectively, as compared with 13.2% and 13.9% of total revenues for the three and six months ending June 30, 2015.

	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
<u>Sales by Domestic and International</u> (in 000's)				
Domestic	\$ 7,757	\$ 6,312	\$ 14,364	\$ 11,537
International	1,538	962	2,706	1,865
Total	\$ 9,295	\$ 7,274	\$ 17,070	\$ 13,402

Although we have only one reporting segment, management analyzes revenue and other operating metrics across three operating categories.

	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
<u>Sales by Operating Category (in 000's)</u>				
Core	\$ 6,881	\$ 6,407	\$ 13,359	\$ 11,932
OEM	1,648	697	2,589	1,017
J-Plasma	766	170	1,122	453
Total	\$ 9,295	\$ 7,274	\$ 17,070	\$ 13,402

Table of Contents

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance is no guaranty of future results.

***Executive Level Overview***

Bovie Medical Corporation ("Company", "Bovie Medical", "we", "us", or "our") was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 4 Manhattanville Road, Suite #106, Purchase, New York 10577.

We are an energy-based medical device company specializing in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctor's offices, surgery centers and hospitals worldwide. Our medical devices are marketed through Bovie's own well-respected brands (Bovie®, J-Plasma®, IDS™ and ICON™) and on a private label basis to distributors throughout the world. The Company also leverages its expertise in the design, development and manufacturing of electrosurgical equipment by producing equipment for large, well-known medical device manufacturers as well as emerging medical start-ups, through original equipment manufacturing (OEM) agreements.

We are also the developer of J-Plasma®, a patented plasma-based surgical product which we believe has the potential to be a transformational product for surgeons. J-Plasma utilizes a helium ionization process that produces a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents during surgery. While currently in the early stages of commercialization, J-Plasma has been the subject of eleven independent white papers and has been cited therein for its clinical utility in gynecological surgeries and dermatologic/facial plastic surgery procedures.

In March, 2015, the Company closed an underwritten public offering of a total 5,218,749 shares of common stock, par value \$0.001 per share at a price to the public of \$2.50 per share, resulting in net proceeds of approximately \$11.5 million, after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the proceeds from the offering for operating costs, capital expenditures and for general corporate purposes, including working capital. Craig-Hallum Capital Group LLC ("Craig-Hallum") acted as the sole managing underwriter for the offering.

Concurrently with the underwriting, the Company closed on the transactions contemplated under the exchange agreement with certain investors (the "Investors") with respect to which Great Point Partners, LLC acts as investment manager. Pursuant to the terms of the Exchange Agreement, the Company issued 3,588,139 shares of the Company's Series B Convertible Preferred Stock (the "Series B Preferred Stock") in exchange for 3,500,000 shares of the Company's Series A 6% Convertible Preferred Stock and warrants to purchase up to 5,250,000 shares of our common stock in the aggregate which were previously issued in conjunction with the sale of the Company's Series A 6% Convertible Preferred Stock to the Investors in a December 13, 2013 offering, as well as accrued and unpaid preferred dividends. At June 30, 2016, the Series B Preferred Stock is convertible into an aggregate of 3,951,278 shares of the Company's common stock.

The majority of our products currently are marketed through medical distributors, which distribute to more than 6,000 hospitals and to doctors and other healthcare facilities. New distributors are contacted through responses to our advertising in international and domestic medical journals and our presence at domestic and international trade shows.

International sales represented approximately 16.6% and 15.9% of total revenues for the three and six months ended June 30, 2016, as compared with 13.2% and 13.9% of total revenues for the three and six months ending June 30, 2015. Management estimates our products have been sold in more than 150 countries through local dealers coordinated by sales and marketing personnel at our Clearwater, Florida facility. International sales of the company have remained flat, which management attributes to a stronger dollar relative to foreign currencies. In the Middle East and some Latin American countries, lower oil prices negatively impact government funded healthcare, and political and civil unrest in some countries make those markets increasingly volatile and unpredictable.

Table of Contents

During 2014, we commenced full scale commercialization efforts for J-Plasma. As of June 30, 2016, we had a direct sales force consisting of 15 field-based selling positions, and that, coupled with our independent manufacturer's representatives, gives us a total sales force of 42. This is a hospital focused selling organization with its focus on the use of J-Plasma for operating room procedures. On June 30, 2016 the Company entered into a Sales Channel Partnership agreement with Arteriocyte Medical Systems, Inc. to sell J-Plasma to Arteriocyte's network of Plastic Surgeons. As part of our agreement, Arteriocyte agreed to purchase an initial order of ten generators to equip their sales force to use for demonstration purposes. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of J-Plasma.

The Company continuously reviews and refines its marketing strategies and distribution channels, including new sales channel partnerships, regarding the commercialization of J-Plasma technology as well as initiatives to manage expenses and costs as appropriate for market conditions.

We strongly encourage investors to visit our website: [www.boviemedical.com](http://www.boviemedical.com) to view the most current news and to review our filings with the Securities and Exchange Commission.

### **Results of Operations –Three and Six Months Ended June 30, 2016 Compared to Three and Six Months Ended June 30, 2015**

#### *Sales*

	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
<u>Sales by Product Line (in 000's)</u>				
Electrosurgical	\$ 5,078	\$ 4,380	\$ 9,330	\$ 8,119
Cauteries	1,720	1,756	3,554	3,282
Other	2,497	1,138	4,186	2,001
<b>Total</b>	<b>\$ 9,295</b>	<b>\$ 7,274</b>	<b>\$ 17,070</b>	<b>\$ 13,402</b>

#### Sales by Domestic and International (in 000's)

Domestic	\$ 7,757	\$ 6,312	\$ 14,364	\$ 11,537
International	1,538	962	2,706	1,865

Edgar Filing: BOVIE MEDICAL Corp - Form 10-Q

Total	\$	9,295	\$	7,274	\$	17,070	\$	13,402
<u>Sales by Operating Category (in 000's)</u>								
Core	\$	6,881	\$	6,407	\$	13,359	\$	11,932
OEM		1,648		697		2,589		1,017
J-Plasma		766		170		1,122		453
Total	\$	9,295	\$	7,274	\$	17,070	\$	13,402

Table of Contents

Sales for the three and six months ended June 30, 2016 were 27.8% and 27.4% higher than the same respective periods in 2015. For the six months ended June 30, 2016, Core, OEM and J-Plasma sales were 12.0%, 155%, and 147% higher, respectively than the same six month period in 2015.

Core sales benefitted from increased demand from existing customers, growth in our animal health business, and new product offerings. OEM grew from a combination of new and expanded contracts. J-Plasma sales growth reflects continued market adoption and our channel partnership with Arteriocyte.

Our ten largest customers accounted for approximately 56.2% and 57.1% of revenues for the six months ended June 30, 2016 and 2015, respectively. For the six months ended June 30, 2016, McKesson and NDC accounted for 16.5% and 9.6% of our sales, while for the same six month period ended in 2015, McKesson and NDC accounted for 17.7% and 13.2% of our sales, respectively.

*Gross Profit*

	Three Months Ended				Six Months Ended			
	June 30,		Percent of sales		June 30,		Percent of sales	
	2016	2015	2016	2015	2016	2015	2016	2015
(in thousands)								
Cost of sales	\$ 4,595	4,134	49.4%	56.8%	\$ 9,048	7,588	53.0%	56.6%
Gross profit	\$ 4,700	3,140	50.6%	43.2%	\$ 8,022	5,814	47.0%	43.4%

Gross profit increased as a percentage of sales by approximately 7.4% for the three month period ended June 30, 2016 and by approximately 3.6% for the six month period ended June 30, 2016 compared to the same respective periods in 2015. The increase in gross profit was attributable to product mix driven largely by increased sales of J-Plasma generators and OEM contracts.

We do not anticipate any material impact to our gross profit, material costs, or other costs as a result of the effect of inflation or any material impact of changing prices on net revenue.

*Research and Development*

	<b>Three Months Ended</b>		<b>Percent of sales</b>		<b>Six Months Ended</b>		<b>Percent of sales</b>	
	<b>June 30,</b>	<b>June 30,</b>	<b>2016</b>	<b>2015</b>	<b>June 30,</b>	<b>June 30,</b>	<b>2016</b>	<b>2015</b>
	<b>2016</b>	<b>2015</b>			<b>2016</b>	<b>2015</b>		
(in thousands)								
Research and Development	\$ 592	505	6.4%	6.9%	\$ 1,259	951	7.4%	7.1%

Research and development costs increased 17.2% for the three month period ended June 30, 2016 and by 32.4% for the six month period ended June 30, 2016 compared to the same period in 2015. We have incurred increased spending on labor costs, consulting services and other costs as we continue to develop enhancements and complimentary items to our next generation of J-Plasma and core products.

Table of Contents*Professional Fees*

	<b>Three Months Ended</b>		<b>Percent of sales</b>		<b>Six Months Ended</b>		<b>Percent of sales</b>	
	<b>June 30,</b>		<b>2016</b>	<b>2015</b>	<b>June 30,</b>		<b>2016</b>	<b>2015</b>
	<b>2016</b>	<b>2015</b>			<b>2016</b>	<b>2015</b>		
(in thousands)								
Professional services	\$ 396	313	4.3%	4.3%	\$ 753	644	4.4%	4.8%

Our professional fees increased 26.5% for the three month period ended June 30, 2016 and by 16.9% for the six month period ended June 30, 2016 compared to the same period in 2015. The increase was mainly attributable to consulting services.

*Salaries and related costs*

	<b>Three Months Ended</b>		<b>Percent of sales</b>		<b>Six Months Ended</b>		<b>Percent of sales</b>	
	<b>June 30,</b>		<b>2016</b>	<b>2015</b>	<b>June 30,</b>		<b>2016</b>	<b>2015</b>
	<b>2016</b>	<b>2015</b>			<b>2016</b>	<b>2015</b>		
(in thousands)								
Salaries & related costs	\$ 2,200	1,868	23.7%	25.7%	\$ 4,300	3,821	25.2%	28.5%

Salaries and related costs increased 17.7% for the three month period ended June 30, 2016 and by 12.5% for the six month period ended June 30, 2016 compared to the same period in 2015. The increases were primarily a result of additional salaries, benefits and payroll taxes related in our direct sales force, human resources, quality, and research and development departments.

*Selling, General & Administrative Expenses*



Edgar Filing: BOVIE MEDICAL Corp - Form 10-Q

	Three Months Ended		Percent of sales		Six Months Ended		Percent of sales	
	June 30,		2016	2015	June 30,		2016	2015
	2016	2015			2016	2015		
(in thousands)								
SG & A costs	\$ 2,022	2,002	21.8%	27.5%	\$ 4,213	4,219	24.7%	31.5%

Selling, general and administrative costs increased 1.0% for the three month period ended June 30, 2016 and decreased slightly for the six month period ended June 30, 2016 compared to the same period in 2015. Increases in sales commissions, professional services, regulatory compliance and travel and entertainment expenses were offset by decreases in insurance expense.

Table of Contents*Other Income (expense)**Interest Expense*

	<b>Three Months Ended June 30,</b>		<b>Percent of sales</b>		<b>Six Months Ended June 30,</b>		<b>Percent of sales</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
(in thousands)								
Interest expense	\$ (50)	(39)	-0.5%	-0.5%	\$ (88)	(80)	-0.5%	-0.6%
Change in fair value of derivative liabilities	\$ 41	90	0.4%	1.2%	\$ 128	1,534	0.7%	11.4%

*Change in Fair Value of Derivative Liabilities*

At June 30, 2016, we had warrants valued at \$139,275 and we recognized an aggregate gain of approximately \$128,000 for the six months ended June 30, 2016 related to their change in value.

*Income Taxes*

We have not recorded a tax provision for the three months and six months ended June 30, 2016 as we have recorded a full valuation allowance against the net deferred tax assets with a finite life. A valuation allowance is required to be provided to reduce the deferred tax assets to a level which, more likely than not, will be realized. Management evaluated the positive and negative evidence in determining the realizability of the net deferred tax asset. In determining the need for valuation allowance, we reviewed historic operating results, the current period operating results, as well as future income forecasts based on the projections, management concluded that it was not more likely that the Company should realize its net deferred tax assets through future operating results and the reversal of taxable temporary differences. If in the future we determine that we will be able to realize any of the net deferred tax assets,

Edgar Filing: BOVIE MEDICAL Corp - Form 10-Q

we will make adjustment to the valuation allowance, which would increase our income in the period that the determination is made.

*Net Income (loss)*

	Three Months Ended June 30,		Percent of sales		Six Months Ended June 30,		Percent of sales	
	2016	2015	2016	2015	2016	2015	2016	2015
(in thousands)								
Net loss	\$ (519)	(1,497)	-5.6%	-20.6%	\$ (2,463)	(2,375)	-14.4%	-17.7%
Accretion on convertible preferred stock	--	--			--	(222)	--	-1.7%
Gain on conversion of warrants and preferred shares, net	--	--	--	--	\$ --	13,956	--	104.1%
Net income (loss) attributable to common shareholders	\$ (519)	(1,497)			(2,463)	11,359		

A combination of increased sales and improved gross profit margins, coupled with a slowing of our operating expense increase, resulted in a reduced loss of operations compared to the prior year quarter ended June 30, 2015.

Table of Contents

**Product Development**

We have developed most of our products and product improvements internally. Funds for this development have come primarily from our internal cash flow and equity issuances. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and development. New and improved products play a critical role in our sales growth. We continue to emphasize the development of proprietary products and product improvements to complement and expand our existing product lines. Our research and development team members are based in our Florida office and our facility in Sofia, Bulgaria.

**Reliance on Collaborative, Manufacturing and Selling Arrangements**

We manufacture the majority of our products on our premises in Clearwater, Florida. Labor-intensive sub-assemblies and labor-intensive products may be out-sourced to our specifications. Although we sell through distributors, we market our products through national trade journal advertising, direct mail, distributor sales representatives and trade shows, under the Bovie name, the Bovie/Aaron name and private label. Major distributors include Cardinal Health, Independent Medical Co-Op Inc. (IMCO), McKesson Medical Surgical, Inc., Medline, National Distribution and Contracting Inc. (NDC), and Owens & Minor. If any of these distributor relationships are terminated or not replaced, our revenue from the territories served by these distributors could be adversely affected.

We are also dependent on OEM customers who have no legal obligation to purchase products from us. Should such customers fail to give us purchase orders for the product after development, our future business and value of related assets could be negatively affected. Furthermore, no assurance can be given that such customers will give sufficient high priority to our products. Finally, disagreements or disputes may arise between us and our customers, which could adversely affect production and sales of our products.

We also have collaborative arrangements with three key foreign suppliers under which we request the development of certain items and components and we purchase them pursuant to purchase orders. Our purchase order commitments are never more than one year in duration and are supported by our sales forecasts. The majority of our raw materials are purchased from sole-source suppliers. While we believe we could ultimately procure other sources for these components, should we experience any significant disruptions in this key supply chain, there are no assurances that we could do so in a timely manner which could render us unable to meet the demands of our customers, resulting in a material and adverse effect on our business and operating results.

**Liquidity and Capital Resources**

Our working capital at June 30, 2016 was approximately \$15.9 million, a decrease of by approximately \$2.0 million when compared to December 31, 2015. Accounts receivable days of sales outstanding were 43.4 days and 35.7 days at June 30, 2016 and 2015, respectively. The number of day's worth of sales in inventory, which is the total inventory available for production divided by the 12 month average cost of materials, remained steady at 167 days equating to an inventory turn ratio of 2.0 at June 30, 2016 and June 30, 2015, respectively.

On March 17, 2015, we closed our underwritten public offering of 4,800,000 shares of common stock, par value \$0.001 per share at a price to the public of \$2.50 per share, resulting in net proceeds of approximately \$10.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. We intend to use the proceeds from the offering for operating costs, capital expenditures and for general corporate purposes, including working capital. Craig-Hallum acted as the sole managing underwriter for the offering.

On March 31, 2015 Craig-Hallum exercised a portion of its over-allotment option to purchase an additional 418,749 shares of common stock at an aggregate price of \$2.50 per share, resulting in net proceeds of approximately \$900,000. After closing of the over-allotment, the total number of shares sold by the Company in the offering was 5,218,749.

We used cash in operations of approximately \$2.4 million for the six months ended June 30, 2016, compared to cash used in operations of approximately \$4.1 million for the same period in 2015, a decrease of cash used in operations of approximately \$1.7 million which was largely attributable to the change in value of derivative liabilities and working capital.

During the six month period ended June 30, 2016, we used approximately \$41,000 for the purchase of property and equipment as compared to purchases amounting to approximately \$462,000 for the same period in 2015.

Cash used in financing activities for the six month period ended June 30, 2016 of approximately \$60,000 was attributable to the reduction of mortgage note payable. Cash provided by financing activities for the six month period ended June 30, 2015 of approximately \$12.9 million was attributable to the proceeds from the public offering and the exercise of warrants.

Table of Contents

On June 28, 2016, the Company entered into a transaction with Bank of Tampa, a Florida banking corporation ("Lender") wherein Lender amended the terms of a mortgage loan ("the Loan") originally executed on March 20, 2014 with a principal amount of \$3,592,000. The Initial Maturity Date of the Loan was extended to July 20, 2019 from March 19, 2017, and the Extended Maturity Date was amended to July 20, 2024 from March 20, 2022. In addition, the Lender released as collateral to the Loan the Company's working capital accounts in exchange for a negative covenant, limiting the aggregate indebtedness secured by these accounts.

The obligations under the Loan are secured by a first mortgage and security interest in the Company's Clearwater, Florida facility. In addition, the Company has pledged an interest in a certificate of deposit in the amount of \$779,000 as additional collateral. The amount of the additional collateral required declines on a pro rata basis as principal is paid.

Borrowings under the Loan bear interest at LIBOR plus 3.5%, with a fixed monthly principal payment of \$19,956. The interest rate at June 30, 2016 was 3.965%.

The Loan documents contain customary financial covenants, including a covenant that the Company maintains a minimum liquidity of \$750,000. Should we desire to extend the Loan beyond July 20, 2019, we must maintain a Debt Service Coverage Ratio for each of the preceding four quarters of not less than 1.0 to 1.0.

Our future contractual obligations for agreements with initial terms greater than one year and agreements to purchase materials in the normal course of business are summarized as follows (in thousands):

Description	Year Ending December 31,					
	2016	2017	2018	2019	Thereafter	
Purchase commitments	\$ 3,482	\$ -	\$ -	\$ -	\$ -	\$ -
Mortgage debt	239	239	239	2,336	-	-
Total	\$ 3,721	\$ 239	\$ 239	\$ 2,336	\$ -	\$ -

We are continuing to make substantial investments in the development and marketing of our J-Plasma technology for the long term benefit of the Company and its stakeholders, and this may adversely affect our short term profitability and cash flow, particularly over the next 12 to 24 months. While we believe that these investments have the potential to generate additional revenues and profits in the future, there can be no assurance that J-Plasma will be successful or that such future revenues and profitability will be realized.

## Critical Accounting Estimates

In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our report on Form 10-K for the year ended December 31, 2015, which we filed on March 18, 2016.

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, fair valued liabilities, sales returns and discounts, and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made, and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

### *Inventory reserves*

When necessary, we maintain reserves for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience, and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.

## Table of Contents

### *Long-lived assets*

We review long-lived assets which are held and used, including property and equipment and intangible assets, for impairment whenever changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Such evaluations compare the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset over its expected useful life and are significantly impacted by estimates of future prices and volumes for our products, capital needs, economic trends and other factors that are inherently difficult to forecast. If the asset is considered to be impaired, we record an impairment charge equal to the amount by which the carrying value of the asset exceeds its fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique.

### *Liabilities valued at fair value*

Certain financial instruments, such as warrants, which are indexed to our common stock, are classified as liabilities when either: (a) the holder possesses rights to net-cash settlement or (b) physical or net-share settlement is not within our control. In such instances, net-cash settlement is assumed for financial accounting and reporting purposes, even when the terms of the underlying contracts do not provide for net-cash settlement. Such financial instruments are initially recorded, and continuously carried, at fair value (see Note 5 of the consolidated financial statements).

Determining the fair value of these instruments involves judgment and the use of certain relevant assumptions including, but not limited to, interest rate risk, historical volatility and stock price, estimated life of the derivative, anti-dilution provisions, and conversion/redemption privileges. The use of different assumptions or changes in those assumptions could have a material effect on the estimated fair value amounts.

### *Stock-based compensation*

Under our stock option plan, options to purchase common shares of the Company may be granted to key employees, officers and directors of the Company and non-employees by the Board of Directors. The Company accounts for stock options in accordance with FASB ASC Topic 718-10-10, with compensation expense amortized over the vesting period based on the trinomial lattice option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of our expense.

### *Litigation Contingencies*



From time to time, we are exposed to claims and litigation arising in the ordinary course of business and use various methods to resolve these matters in a manner that we believe serves the best interest of the Company and our stockholders. There can be no assurance these actions or other third party assertions will be resolved without costly litigation, or in a manner that is not adverse to our financial position. We do not believe that any of the currently identified claims or litigation matters will have a material adverse impact on our results of operations, cash flows or financial condition. However, given uncertainties associated with any litigation, if our assessments prove to be wrong, or if additional information becomes available such that we estimate that there is a possible loss or possible range of loss associated with these contingencies, then we would record the minimum estimated liability, which could materially impact our results of operations, financial position and cash flows.

### *Income taxes*

We utilize the liability method of accounting for income taxes as set forth in FASB ASC 740. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. Management evaluated the positive and negative evidence in determining the realizability of the net deferred tax asset. In determining the need for valuation allowance, we reviewed historic operating results, updated current period actual results, as well as future income forecasts based on the projections, management concluded that it was not more likely that the Company should realize its net deferred tax assets through future operating results and the reversal of taxable temporary differences.

If in the future we determine that we will be able to realize any of the net deferred tax assets, we will make adjustment to the valuation allowance, which would increase our income in the period that the determination is made.

Table of Contents

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.

*Inflation*

Inflation has not materially impacted the operations of our Company.

*Off-Balance Sheet Arrangements*

We have no off-balance sheet arrangements at this time.

*Recent Accounting Pronouncements*

See Note 4 of the consolidated financial statements.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Our short-term investments consist of cash and cash equivalents. As such we do not believe we are exposed to significant interest rate risk. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. If a 10% change in interest rates were to have occurred on June 30, 2016, this change would not have had a material effect on the fair value of our investment portfolio as of that date.

**ITEM 4. CONTROLS AND PROCEDURES**

## **Evaluation of Disclosure Controls and Procedures**

We have carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of June 30, 2016. Based upon that evaluation, our CEO and CFO concluded that, as of the end of that period, our disclosure controls and procedures are effective in providing reasonable assurance that (a) the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and (b) such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

## **Changes in Internal Controls**

There were no changes in our internal control over financial reporting (as defined in Rules 13(a)-15(f) and 15(d)-15(f)) during the three months ended June 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

**PART II. OTHER INFORMATION ITEM**

**1. LEGAL PROCEEDINGS**

In the normal course of business, we are subject, from time to time, to legal proceedings, lawsuits and claims. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. If any of these matters arise in the future, it could affect the operating results of any one or more quarters.

We expense costs of litigation related to contingencies in the periods in which the costs are incurred.

**ITEM 1A. RISK FACTORS**

There have been no material changes to the risk factors previously disclosed in our Form 10-K for the year ended December 31, 2015, in response to Item 1A to Part 1 of Form 10-K.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

## ITEM 5. OTHER INFORMATION

None.

## ITEM 6. EXHIBITS

10.1*	Amendment No. 1 to Employment Agreement of Jack McCarthy.
10.2**	First Amendment to Loan Agreement with the Bank of Tampa.
10.3**	Amended and restated Promissory Note.
10.4**	Mortgage and Modification Agreement with the Bank of Tampa.
31.1	<u>Certifications of Robert L. Gershon, Chief Executive Officer of Registrant pursuant to Rule 13a-14 adopted under the Securities Exchange Act of 1934, as amended, and Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2	<u>Certifications of Jay D. Ewers, Chief Financial Officer of Registrant pursuant to Rule 13a-14 adopted under the Securities Exchange Act of 1934, as amended, and Section 302 of the Sarbanes-Oxley act of 2002.</u>
32.1	<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
32.2	<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.1	Financial Statements from the Quarterly Report on Form 10-Q of Bovie Medical Corporation for the three months ended June 30, 2016, filed on August 2, 2016, formatted in XBRL.

---

\* Incorporated by reference for Registrant's Report on Form 8-K filed with the Commission April 24, 2016.

\*\* Incorporated by reference for Registrant's Report on Form 8-K filed with the Commission on July 5, 2016.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**Bovie Medical Corporation**

Dated: August 2, 2016

By: */s/ Robert L. Gershon*  
Robert L. Gershon  
Chief Executive Officer  
(Principal Executive Officer)

Dated: August 2, 2016

By: */s/ Jay D. Ewers*  
Jay D. Ewers  
Chief Financial Officer,  
Treasurer, and Secretary  
(Principal Financial Officer)